Prakash Gaba of prakashgaba.com is of the view that one may stay invested in Venus Remedies.
Gaurang Shah of Geojit Financial Services is of the view that one may prefer Granules India.
Price to book value measure is used for those companies whose present value of the assets cannot be truly reflected in the book value. For banks’ valuation, P/BV is most suited given its borrowing business model and narrow RoE structure.
SP Tulsian of sptulsian.com, in an interview to CNBC-TV18, gave his views on various stocks.
Watch the interview of Vishal Malkan, CMT at malkansview.com and Lancelot D'Cunha, CEO of ITI Wealth Management Pvt Ltd with Reema Tendulkar & Sumaira Abidi on CNBC-TV18, in which they spoke about specific stocks and sectors.
Lancelot D'Cunha, CEO at ITI Wealth management is of the view that one may exit Venus Remedies.
Manav Chopra of Nirmal Bang recommends buying Biocon for a target price of Rs 520 and Venus Remedies for a target price of Rs 370.
Dharmesh Kant, IndiaNivesh Securities Private Limited advises buying Tamil Nadu Newsprint and Papers for a target price of Rs 172 and Pratibha Industries for a target price of Rs 73.
Lancelot D Cunha of ITI Wealth Management recommends buying LIC Housing Finance with a target of Rs 172 and advises selling Tech Mahindra August Futures.
Shahina Mukadam of Varun Capital recommended buying Tata Global Beverage with a target price of Rs 152 and Jet Airways with a target price of Rs 352.
Tata Motors may slip to Rs 225, says Anil Manghnani, Modern Shares & Stock Brokers.
Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.
Venus Remedies may rally to Rs 225 in a year‘s time, says SP Tulsian, sptulsian.com.